Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Amneal Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Amneal Pharmaceuticals, Inc.

AMRX

Amneal Pharmaceuticals, Inc.

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in developing, manufacturing, marketing, and distributing a broad portfolio of essential medicines. Its business segments include Affordable Medicines (generics, injectables, biosimilars), Specialty branded pharmaceuticals focused on central nervous system and endocrine disorders, and AvKARE, a pharmaceutical distributor serving U.S. government and institutional markets. Amneal leverages complex formulations, vertical integration, and regulatory expertise to deliver cost-effective, high-value pharmaceutical products primarily in the U.S., India, and Ireland.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Amneal Pharmaceuticals, Inc.

1
1
Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals Reports $722.5M Revenue and Announces Acquisition of Kashiv BioSciences

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals Reports $3.02 Billion Revenue, 8% Increase for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals Reports $784.5M Revenue in Q3 2025, 11.7% Increase Year-Over-Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals Reports 3.2% Revenue Growth to $724.5 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals Reports $695.4M Revenue and $24.6M Net Income in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals Reports 13.3% Revenue Growth in Q3 2024, Despite Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments